MX2017008983A - Composición farmaceútica de sulfonamida. - Google Patents

Composición farmaceútica de sulfonamida.

Info

Publication number
MX2017008983A
MX2017008983A MX2017008983A MX2017008983A MX2017008983A MX 2017008983 A MX2017008983 A MX 2017008983A MX 2017008983 A MX2017008983 A MX 2017008983A MX 2017008983 A MX2017008983 A MX 2017008983A MX 2017008983 A MX2017008983 A MX 2017008983A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
sulfonamide
sulfonamide compound
injectable preparation
present
Prior art date
Application number
MX2017008983A
Other languages
English (en)
Inventor
Tian Li
Zhao Xinying
Sun Changhai
Juang WU Yi
Han Zhidong
Lin Chuangyu
Yao Xiaoqing
Original Assignee
Tianjin Hongri Jian Da Kang Medical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hongri Jian Da Kang Medical Tech Co Ltd filed Critical Tianjin Hongri Jian Da Kang Medical Tech Co Ltd
Publication of MX2017008983A publication Critical patent/MX2017008983A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica de sulfonamida. La presente invención se relaciona a una preparación inyectable del compuesto de sulfonamida que comprende un compuesto de sulfonamida o un derivado del mismo. La preparación inyectable es preparada a partir del compuesto de sulfonamida y un portador farmacéuticamente aceptable a través de ciertas tecnologías de preparación. La preparación inyectable del compuesto de sulfonamida involucrada en la presente invención es estable y controlable en calidad y efectiva.
MX2017008983A 2015-01-06 2016-01-04 Composición farmaceútica de sulfonamida. MX2017008983A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510005995.5A CN104473914B (zh) 2015-01-06 2015-01-06 一种磺酰胺类药物组合物
PCT/CN2016/070015 WO2016110225A1 (zh) 2015-01-06 2016-01-04 一种磺酰胺类药物组合物

Publications (1)

Publication Number Publication Date
MX2017008983A true MX2017008983A (es) 2018-03-23

Family

ID=52748619

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008983A MX2017008983A (es) 2015-01-06 2016-01-04 Composición farmaceútica de sulfonamida.

Country Status (11)

Country Link
US (2) US20170354621A1 (es)
EP (1) EP3243510B1 (es)
JP (1) JP6502507B2 (es)
KR (1) KR101949810B1 (es)
CN (2) CN104473914B (es)
AU (1) AU2016206154B2 (es)
CA (1) CA2972834C (es)
MX (1) MX2017008983A (es)
RU (1) RU2715700C2 (es)
SG (1) SG11201705543VA (es)
WO (1) WO2016110225A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104473914B (zh) * 2015-01-06 2017-01-11 天津红日药业股份有限公司 一种磺酰胺类药物组合物
CN113368251A (zh) * 2020-02-25 2021-09-10 上海和绎实业有限公司 一种组合溶剂及其制备方法和应用
US11752160B2 (en) * 2020-09-24 2023-09-12 Gongwin Biopharm Co., Ltd Method for reducing fat by administering benzenesulfonamide compositions
US20230098310A1 (en) * 2021-09-29 2023-03-30 Gongwin Biopharm Co., Ltd Methods for treating mast cell tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891454A (en) * 1997-03-28 1999-04-06 Alexander Wu Anti-cancer drug and special tumor necrotizing agent
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
CN1073415C (zh) 1997-07-03 2001-10-24 吴宜庄 磺酰胺类化合物在制备抗癌药物中的应用
JP2002505307A (ja) * 1998-03-05 2002-02-19 ファレス ファーマシューティカル リサーチ エヌブイ 薬学的組成物およびその使用
US6727287B2 (en) 2001-04-16 2004-04-27 Pts International, Inc. Toluene sulfonamide-containing anti-tumor composition and method of use thereof
CN102389410A (zh) * 2011-11-03 2012-03-28 黄漫翔 对-甲苯磺酰胺在制备癌症治疗药物中的应用
CN104473914B (zh) * 2015-01-06 2017-01-11 天津红日药业股份有限公司 一种磺酰胺类药物组合物

Also Published As

Publication number Publication date
RU2715700C2 (ru) 2020-03-03
CN104473914B (zh) 2017-01-11
KR20170095926A (ko) 2017-08-23
SG11201705543VA (en) 2017-08-30
WO2016110225A1 (zh) 2016-07-14
EP3243510A4 (en) 2018-08-08
JP6502507B2 (ja) 2019-04-17
CA2972834C (en) 2020-07-14
US20190231721A1 (en) 2019-08-01
EP3243510B1 (en) 2022-08-31
RU2017126976A3 (es) 2019-08-22
RU2017126976A (ru) 2019-02-08
JP2018501291A (ja) 2018-01-18
CN104473914A (zh) 2015-04-01
AU2016206154B2 (en) 2018-11-01
CA2972834A1 (en) 2016-07-14
EP3243510A1 (en) 2017-11-15
KR101949810B1 (ko) 2019-02-19
US20170354621A1 (en) 2017-12-14
US11040020B2 (en) 2021-06-22
AU2016206154A1 (en) 2017-07-27
CN107205974A (zh) 2017-09-26

Similar Documents

Publication Publication Date Title
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
PH12016501122A1 (en) Delayed release compositions of linaclotide
GEP20207075B (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
EP3206706A4 (en) Stable injectable composition of pharmaceutically active agents and process for its preparation
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
IN2014CH00840A (es)
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
MX2017008983A (es) Composición farmaceútica de sulfonamida.
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
EA201691741A1 (ru) Фармацевтическая композиция
PL3176164T3 (pl) Izomer optyczny pochodnej 1-tlenku 1,4-benzotiazepiny oraz farmaceutyczna kompozycja wytworzona z jego użyciem
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
IN2014MU00859A (es)
MX2016005539A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
WO2015181837A3 (en) Novel compounds as anti-tubercular agents
IN2013MU03308A (es)
IN2013CH04314A (es)
MX2016013428A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
PH12019501689A1 (en) Composition comprising immediate release and extended release capecitabine
ZA202003079B (en) Pharmaceutical compositions comprising safinamide
ZA201803722B (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
FG Grant or registration